Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 October 2020 | Story Leonie Bolleurs | Photo Supplied
Qinisani Qwabe, one of the Mail & Guardian Top 200 Young South Africans, considers it important to always reach out and contribute to someone's life, no matter how small it may be.

Looking back at 2020, most people will not have fond memories. But for Qinisani Qwabe, a second-year PhD student in the Centre for Sustainable Agriculture, Rural Development and Extension, 2020 turned out to be a good year.

On 10 September, he heard that he was selected as one of the Mail & Guardian Top 200 Young South Africans in the education category. As if being elected as one of the prestigious group of young people is not enough, Qwabe added another feather in his cap when he was chosen as one of 21 young scientists by the Academy of Science of South Africa (ASSAf), in collaboration with the Department of Science and Innovation (DSI). 

When offered the chance to represent South Africa at a BRICS Conference in Russia, he seized the opportunity with both hands. At this virtual event, he presented a paper on a topic he cares about a lot – ecology. His paper, using a South African case study, was titled: The role of agrobiodiversity on environmental management and its impact on human ecology.

Sustainable resources

From an early age, growing up in a very isolated community called iSihuzu on the outskirts of Richards Bay, Qwabe worked hard. He not only reaped the rewards by seeing all his tuition fees paid, but he was also offered opportunities to make a difference in society. 

“I want to see a society that leads a sustainable life and values its natural resources. This is what wakes me up every morning. That is what I am working towards,” he says.

Qwabe has a registered organisation that, among others, seeks to achieve agricultural biodiversity, respect and value for local knowledge, sustainable development, as well as youth and community engagement.  

The organisation has two legs – one dealing with agricultural production and the other focusing on social entrepreneurship. “As part of this social entrepreneurship initiative, we are working with schools in the north of KwaZulu-Natal, where we do outreach programmes (e.g. donating school uniforms), and run projects driven towards sustainability,” says Qwabe.

But he believes that it is his voice on indigenous foods, together with his passion for research – complemented by community development initiatives – that contributed to his selection as one of Mail & Guardian’s top 200 Young South Africans. 

A greater vision

He is happy to be in the academia and believes that it will propel him towards his greater vision. 

“My vision for my future is to be well-known for my contributions on matters of environmental sustainability, and equally so, for community development. Parallel to my philanthropic undertakings, I envision being a leader in one of the leading organisations on environmental sustainability, such as the World Health Organisation's Food and Agricultural Organisation (FAO),” says Qwabe. 

Here he would like to focus his energies on food security, nutrition, and food safety; sustainable management and use of natural resources and forestry; and institutional capacity building for the sustained management of natural resources and increased agriculture production.

The next generation

Qwabe believes he is making an impact and building a solid foundation for the upcoming generations to build upon.  He urges the youth of South Africa to strive to make a difference. “No matter how small it might seem,” he says.

“To borrow from the American songwriter, Michael Jackson – WE are the world. And that 'WEness' denotes that each one of us has a role to play.

 

 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept